中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2013年
3期
10-12
,共3页
皮炎%特应性%中西医结合%随机对照试验%疗效
皮炎%特應性%中西醫結閤%隨機對照試驗%療效
피염%특응성%중서의결합%수궤대조시험%료효
Dermatitis%Atopic%Integrative medicine%Randomized controlled trial%Efficacy
目的:评价中西医结合治疗特应性皮炎(AD)的疗效.方法:采用多中心、随机对照平行设计,将146例 AD患者随机分为研究组和对照组,分别用中西医结合(氯雷他定内服+糠酸莫咪松霜外用+中药内服)治疗和仅用西药治疗,疗程4周.治疗结束时行基于研究者总体评估(IGA)评分,于疗前及疗后第 l、2,3、4周时访视湿疹面积与严重度指数(EASI)评分,随访治疗成功者12个月内的复发情况.结果:①治疗结束时研究组 IGA 评分0、1、2、3、4和5级者分别是5、18、32、13、4和1例,对照组分别是2、9、34、12、10 和 6例,差异有统计学意义,Z=-2.753,P=0.006.②随着治疗时间的延长,EASI 评分逐渐降低(F=184.36,P=0.000),且研究组降低程度大于对照组(F=18.156,P=0.000).③研究组和对照组治疗成功者12个月内的累计复发率分别是39.13%和81.82%,对照组复发的风险是研究组的3.118倍(HR=3.118),P=0.017.结论:中西结合治疗AD 较单纯西药治疗具有较佳的改善症状体征、降低复发的效果.
目的:評價中西醫結閤治療特應性皮炎(AD)的療效.方法:採用多中心、隨機對照平行設計,將146例 AD患者隨機分為研究組和對照組,分彆用中西醫結閤(氯雷他定內服+糠痠莫咪鬆霜外用+中藥內服)治療和僅用西藥治療,療程4週.治療結束時行基于研究者總體評估(IGA)評分,于療前及療後第 l、2,3、4週時訪視濕疹麵積與嚴重度指數(EASI)評分,隨訪治療成功者12箇月內的複髮情況.結果:①治療結束時研究組 IGA 評分0、1、2、3、4和5級者分彆是5、18、32、13、4和1例,對照組分彆是2、9、34、12、10 和 6例,差異有統計學意義,Z=-2.753,P=0.006.②隨著治療時間的延長,EASI 評分逐漸降低(F=184.36,P=0.000),且研究組降低程度大于對照組(F=18.156,P=0.000).③研究組和對照組治療成功者12箇月內的纍計複髮率分彆是39.13%和81.82%,對照組複髮的風險是研究組的3.118倍(HR=3.118),P=0.017.結論:中西結閤治療AD 較單純西藥治療具有較佳的改善癥狀體徵、降低複髮的效果.
목적:평개중서의결합치료특응성피염(AD)적료효.방법:채용다중심、수궤대조평행설계,장146례 AD환자수궤분위연구조화대조조,분별용중서의결합(록뢰타정내복+강산막미송상외용+중약내복)치료화부용서약치료,료정4주.치료결속시행기우연구자총체평고(IGA)평분,우료전급료후제 l、2,3、4주시방시습진면적여엄중도지수(EASI)평분,수방치료성공자12개월내적복발정황.결과:①치료결속시연구조 IGA 평분0、1、2、3、4화5급자분별시5、18、32、13、4화1례,대조조분별시2、9、34、12、10 화 6례,차이유통계학의의,Z=-2.753,P=0.006.②수착치료시간적연장,EASI 평분축점강저(F=184.36,P=0.000),차연구조강저정도대우대조조(F=18.156,P=0.000).③연구조화대조조치료성공자12개월내적루계복발솔분별시39.13%화81.82%,대조조복발적풍험시연구조적3.118배(HR=3.118),P=0.017.결론:중서결합치료AD 교단순서약치료구유교가적개선증상체정、강저복발적효과.
Objective: To investigate the efficacy of integrative medicine on treating atopic dermatitis. Methods: 146 AD patients were randomly divided into two groups. The control group was given Loratadine for oral use and Mometasone furoate for external use, while the treated group was given TCM for oral use more. After treatment, the IGA scores were undertaken. And the patients were selected to follow-up visit for 12 months based on the EASI scores. Results: After treatment, there were 5, 18, 32, 13, 4 and 1 cases of the IGA scores 0, 1,2,3,4 and 5 respectively in the treated group, while in the control group were 2,9,34, 12, 10 and 6 cases respectively, with significant differences (Z=-2.753, P=0.006). EASI scores stepped down along with the therapy time, and the reduction degree in the treated group was much greater than that in the control group (F=18.156, P=0.000). The accumulative recurrence rates in 12 months in the treated group and the control group were 39.13% and 81.82% respectively. That in the treated group was 3.118 times as much as that in the control group (P=0.017). Conclusion: The integrative medicine had more effective and lower recurrence rates than simple modern medicine on AD therapy.
